Less is more - Research into anti-angiogenic therapies for treating cancer has finally had its first breakthroughs. But it may also influence the way in which classical chemotherapy is used for cancer treatment

被引：4

作者：

Brower, V

机构：

来源：

EMBO REPORTS | 2003年 / 4卷 / 09期

关键词：

D O I：

10.1038/sj.embor.embor934

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：831 / 834

页数：5

共 4 条

[1] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[2] Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:: antitumor activity and correlation with vascular endothelial growth factor levels [J].

Colleoni, M ;

Rocca, A ;

Sandri, MT ;

Zorzino, L ;

Masci, G ;

Nolè, F ;

Peruzzotti, G ;

Robertson, C ;

Orlando, L ;

Cinieri, S ;

de Braud, F ;

Viale, G ;

Goldhirsch, A .

ANNALS OF ONCOLOGY, 2002, 13 (01) :73-80

[3]

FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182

[4]

Man S, 2002, CANCER RES, V62, P2731

← 1 →